Seekingalpha:
- ACADIA Pharmaceuticals (ACAD +8.9%) has recorded the biggest intraday gain since March after Guggenheim raised its rating on the biotech to Buy from Neutral.
- The analyst Yatin Sunejaa has a favorable view on the company’s upcoming Phase 3 topline data read for its Rett syndrome candidate trofinetide scheduled for Q4 2021.
- “Given the limited investor interest in this program, we like the risk-reward heading into the readout,” Sunejaa wrote with the price target of $23 per share of Acadia (NASDAQ:ACAD), implying a premium of ~28.1% to the last close.
- In addition to the Phase II study, “one more successful trial will be sufficient to file an NDA in 2022,” the firm noted, citing the company management.
- In March 2020, Acadia (ACAD) announced that the FDA granted the Rare Pediatric Disease designation to trofinetide in the treatment of Rett syndrome.
Now +12%
Share Price, page-56
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.32 |
Change
0.500(2.52%) |
Mkt cap ! $2.587B | |||
| Open | High | Low | Value | Volume |
| $19.89 | $20.39 | $19.77 | $4.036M | 200.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 173 | $20.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.32 | 88 | 6 |
View Market Depth
| Last trade - 14.39pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.27 |
Change
0.500 ( 2.66 %) |
||||
| Open | High | Low | Volume | ||
| $19.86 | $20.40 | $19.77 | 70653 | ||
| Last updated 14.57pm 07/05/2024 ? | |||||
| NEU (ASX) Chart |